

Functional Impairment and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study

Journal: Quality of Life Research

¹Janet H. Ford, ¹Virginia L. Stauffer, ²Peter McAllister, ³Sreelatha Akkala, ¹Matthew Sexson,

¹David W. Ayer, ¹Shufang Wang

¹Eli Lilly and Company, Indianapolis, IN, USA

²New England Institute for Neurology and Headache, Stamford, USA

³Eli Lilly Services India Pvt Ltd, Bengaluru, India

Corresponding Author:

Janet H. Ford

Eli Lilly and Company

893 S. Delaware Street

Indianapolis, IN 46225, USA

Phone: 317-903-8199

Email: ford_janet@lilly.com

Supplementary material

Online resource: List of institutional review boards at each study site

Commissie Medische Ethiek Universitair Ziekenhuis [Institutes: Clinique St. Joseph, Algemeen Ziekenhuis St Jan Brugge, Universitair Ziekenhuis Brussel; Belgium], IRB Services [Institutes: DIEX Recherche Sherbrooke, Inc., Stroyan Research; Canada], Conjoint Medical Ethics Committee [Institute: University of Calgary, Canada], CPP Sud Méditerranée V [Institutes: CHU St Etienne Hôpital Nord, Hôpital de la Timone, Hôpital de Cimiez, Hôpital Lariboisière; France], Egeszsegügyi Tudományos Tanács [Institutes: Országos Idegtudományi Intézet, Petz Aladar Megyei Oktató Kórház, SE Neurológiai Klinika, Valeomed Kft.; Hungary], Quorum Review, Inc. [Institutes: Wilmington Health Associates, Mercy Health Research, Blue Ridge Research Center, Jacksonville Center for Clinical Research, Ericksen Research and Development, Suburban Research Associates, California Medical Clinic for Headache, Albuquerque Neuroscience, Inc., ClinPoint Trials, LLC, Encompass Clinical Research, New England Institute for Clinical Research, Infinity Clinical Research, LLC, PharmQuest, Ponce School of Medicine CAIMED Center; USA]